This time, it was a boardroom clear-out and the surprise return of Lars Rebien Sorensen. The one-time chief executive officer is taking the role of chairman in an unprecedented power grab at the top ...

Oct 15 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and Omeros (OMER.O), opens new tab have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

Novo Nordisk NOVO.B2.49%increase; green up pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. A troubled Indiana ...

Novo Nordisk said Thursday it was buying US biotech firm Akero Therapeutics, which is developing treatments for a number of metabolic diseases, for $4.7 billion. The Danish firm, the maker of ...

Novo Nordisk is acquiring Akero Therapeutics for up to $5.2bn, aiming to diversify beyond semaglutide and strengthen its position in MASH and cirrhosis. The deal brings Akero's EFX, a promising FGF21 ...